These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26642212)

  • 1. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
    Ali TB; Schleret TR; Reilly BM; Chen WY; Abagyan R
    PLoS One; 2015; 10(12):e0144337. PubMed ID: 26642212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
    Tavassoli N; Sommet A; Lapeyre-Mestre M; Bagheri H; Montrastruc JL
    Drug Saf; 2007; 30(11):1063-71. PubMed ID: 17973542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
    Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
    Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
    Mohammad D; Chan P; Bradley J; Lanctôt K; Herrmann N
    Expert Opin Drug Saf; 2017 Sep; 16(9):1009-1019. PubMed ID: 28678552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System.
    Morris R; Umeukeje G; Bu K; Cheng F
    J Alzheimers Dis; 2021; 83(3):1061-1071. PubMed ID: 34397417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
    Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
    J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
    Bu K; Patel D; Morris R; Han W; Umeukeje G; Zhu T; Cheng F
    J Alzheimers Dis; 2022; 89(2):721-731. PubMed ID: 35964196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    Drugs Aging; 2022 Jun; 39(6):453-465. PubMed ID: 35666463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study.
    Zannas AS; Okuno Y; Doraiswamy PM
    Pharmacotherapy; 2014 Mar; 34(3):272-8. PubMed ID: 24127392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
    Kose E; Yamamoto T; Tate N; Ando A; Enomoto H; Yasuno N
    Pharmazie; 2023 May; 78(5):42-46. PubMed ID: 37189266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
    Lockhart IA; Mitchell SA; Kelly S
    Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.